An interventional study of Gaze Contingent Music Reward Therapy and Escitalopram in Social Anxiety Disorder, sponsored by Tel Aviv University. Completed at 1 site in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-01.
Sponsored by Tel Aviv University · Not applicable, Interventional, and Treatment
Among 14 studies in Phobia, Social with a site in Israel — 2 open to participants now, 2 under way, none of them phase 3. Phobia, Social · Israel.
Among the 14 studies in Phobia, Social with a site in Israel, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 12 with no phase, and was the 8th registered.
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
Browse Phobia, Social studies →2 of the 14 studies in Phobia, Social with a site in Israel are open now. Recruiting first, the newest first:
Tel Aviv University · Sites in Israel
Ages 18–65
University of Haifa · Sites in Israel
Ages 18–45
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2018.
This study's enrollment of 105 is above the median of 76 across 339 interventional studies indexed under Phobia, Social.
Median enrollment 75 across the 14 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 5 most frequent:
Tel Aviv University is the lead sponsor of 101 studies on the registry; 27 are open to participants now.
Tel Aviv University has 9 studies filed under Phobia, Social — fewer than ten, so there is no comparison to draw.
1 of the studies in Phobia, Social with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07325929University of HaifaOnline Radical Acceptance Intervention for Social Anxiety Disorder | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Phobia, Social with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the clinical efficacy and neuro-cognitive mechanisms of Gaze-Contingent Usic Reward Therapy for social anxiety disorder, compared with treatment with SSRIs or waitlist control.
Attention biases in threat processing have been assigned a prominent role in the etiology and maintenance of anxiety disorders. The purpose of this study is to determine whether giving gaze-contingent feedback is an effective treatment for social anxiety disorder, compared to treatment with SSRI (Escitelopram) and a waitlist control. A secondary purpose is to explore the unique neuro-cognitive mechanisms of this treatment, using eye-tracking, MRI and fMRI measurements. Participants will be assessed using clinical interviews and self-rated questionnaires before, during and after 12 weeks of treatment or wait. Outcome measures will be social anxiety symptoms, as well as dwell time on threat in eye-tracking paradigms tested in previous studies, and BOLD signals in MRI measurements. Neuro-cognitive mechanisms will be explored as potential mediators of clinical efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
Behavioral: Gaze Contingent Music Reward Therapy
Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
Drug: Escitalopram
Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
Behavioral: Waitlist
Feedback according to participants' viewing patterns, in order to modify their attention.
10-20 mg of Escitalopram
Also known as: Cipralex
Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
Change from baseline - the Liebowitz Social Anxiety Scale - Diagnostic Interview scores
The LSAS is a 24-item scale, each item corresponding to a situation selected on the basis of clinical experience. Each item is rated on a severity scale ranging from 0 to 3 with regard to the passing week, measuring separately two components of social anxiety, specifically, fear/anxiety and avoidance of social interaction and performance situations. Although the assessor may request and ask for further detail and adjust the rating based on clinical experience, this option is not often exercised, and inter-rater agreement is not considered to be a relevant concern.
Time frame: 6 weeks into intervention, 1 week after intervention completion
Change from baseline - the Social Phobia Inventory scores
This is a 17-item self-report measure of social anxiety evaluating fear, avoidance and physiological discomfort. Each item is rated on scale ranging from 0 to 4 with a possible total score of 68.
Time frame: At baseline, at weeks 2,4,6,8,10 of the intervention or wait period, 1 week after intervention completion
Clinical Global Impression
A global measure of clinician impression improvement and severity of illness, ranging from 1 to 7.
Time frame: 6 weeks into intervention, 1 week after intervention completion
Change from baseline - the Patient Health Questionnaire (PHQ)- a measure of depression
Depression levels at pre and posttreatment and their change from baseline were used as moderators for clinical outcome
Time frame: at baseline, one week after end of intervention
Change from baseline - viewing patterns on threat-neutral face matrices
gaze patterns, and specifically attention allocation to threat, at pre, mid and posttreatment and their change from baseline were used as moderators for clinical outcome, as well as indicators of target engagement for the GCMRT group. This is done using an established eye-tracking task (Lazarov et al, 2016). Data will also be extracted from the training sessions of GC-MRT participants to evaluate change during treatment.
Time frame: at baseline, 6 weeks into intervention and one week after end of intervention
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Dec 2021, 40 months.
Of 142 non-industry interventional studies with no phase under Phobia, Social, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 44. This study's 40 months is above that.
Counting every sponsor, half of 148 studies reached it within 28 months; a quarter within 14 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.